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ABSTRACT 
Diabetes mellitus (DM) is a growing global disorder associated with several 
complications that include micro- and macrovascular disturbances. Conditions affecting 
the foot make up one of the major complications of the disease. The overall aim of this 
thesis was to investigate how developed the diabetic foot care is in Sweden, with the 
ultimate goal being to identify areas needing improvement. 
This thesis is based on two papers:  
In Paper I, a national inventory was made of a caregiver’s organization for diagnosis 
and treatment of diabetic osteoarthropathy, using a questionnaire addressed to all 
Swedish hospitals with an emergency department for orthopedic patients. There was a 
95% response rate. Three respondents reported never having had any contact with 
patients with diabetic osteoarthropathy, resulting in an analysis of 57 questionnaires. 
Most of the respondents (79%) specified an absence of established procedures for 
managing patients with osteoarthropathy. The most common diagnostic method was 
clinical diagnosis and conventional plain radiography (95%). MRI or scintigraphy was 
used by 19% and 10.5% of the respondents, respectively. As a treatment method, 84% 
used a total contact cast, and 38% orthoses. Two clinics indicated a treatment duration 
of less than 3 months, thirty clinics (53%) a treatment duration of 3-6 months, and 
sixteen clinics (28%) a duration of 6-12 months. Only four clinics indicated duration 
longer than 12 months, while two clinics did not provide any treatment. We noticed a 
lack of adequate guidelines for the optimal management of diabetes osteoarthropathy. 
In Paper II, the objective was by a questionnaire to investigate at a national level the 
organization of multidisciplinary team (MDT) care of patients with diabetes mellitus 
(DM) and foot complications in all Swedish hospitals, and to what extent they are in 
line with the Stockholm Consensus Statement from an 1998 assembled expert panel on 
how to organize treatment and prevention of foot lesions in patients with DM. 
The response rate was 92 %. Eighty-four percent of the responding hospitals have a foot 
team. Most of the teams have access to an internal medicine specialist, chiropodist and 
orthotist. Fewer teams have reported access to an orthopaedic surgeon and infectious 
disease specialist, and only half to a vascular surgeon. In the joint MDT evaluations of 
outpatients, the majority report regular input of an internal medicine specialist, 
  
 
 
podiatrist and orthotist. Approximately 50 % report presence of an infectious disease 
specialist and orthopaedic surgeon, but only a few of a vascular surgeon. When 
evaluating hospitalized patients there is a reduction in attendance of all specialists. 
There is low registration of amputation rate and healed foot ulcers. The existence of 
adequate guidelines could not be confirmed. 
Conclusion: The inventory of the management of patient with DM and osteoarthropathy 
indicates a national need for an improvement in knowledge as well as guidance 
regarding the early diagnosis and optimal treatment of this condition. Regarding the 
recommendations in the Stockholm Consensus Statement, they are mostly adopted 
among large and medium-sized hospitals in contrast to small, which could reflect an 
unequal health care at a national level. Vascular surgeons seldom attend MDT 
evaluations, and there is a low regular input of infectious disease specialists oriented 
toward orthopedic infections. There is a remarkable decrease in attendance of all 
specialists in MDT evaluations of hospitalized patients. We find no support for the 
ability of hospitals to evaluate their work by potential quality control markers. Our 
study indicates that national surveys can be valuable in evaluating healthcare 
organization and management of patient with DM and foot complication. 
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1 INTRODUCTION 
Diabetes mellitus (DM) is one of the most common metabolic disorders in the world, 
having had a substantial increase during the past few decades and with an estimated 
prevalence among adults of 8.4% in 2017 that is predicted to rise to 9.9% in 2045 [1]. 
DM is often accompanied by a broad spectrum of complications, e.g., in such 
cardiovascular diseases as angina pectoris, myocardial infarction, peripheral artery 
disease (PAD), and stroke, but also retinopathy and diabetic foot disease [2]. An 
important factor for patients with DM being able to better control the disease is physical 
activity, e.g., walking [3]. Physical activity has been found to improve both 
psychological and physiologic conditions. In order to exercise and walk, it is important 
for DM patients to have healthy and usable feet. Walking and staying mobile help to 
improve glucose levels to prevent and better manage type-2 DM [4].  
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2 BACKGROUND  
DM is a metabolic disorder characterized by hyperglycemia that is caused by a defect in 
insulin secretion, resulting in damage, dysfunction and failure to many organs. DM can 
be divided into two types: type-1 DM is caused by a deficiency of insulin secretion, and 
type-2 DM is the result of resistance to insulin and an insufficient compensatory insulin 
secretion response to glucose [5]. 
DM is a global challenge for healthcare due to a growing diabetic population and the 
multiple and long-term complications of the disease that can affect the human body. 
One of these long-term complications is peripheral sensory neuropathy, which carries 
the risk of foot complications such as foot lesions and osteoarthropathy [6]. When 
referring to the variety of pathologic conditions that can affect the feet in patients with 
DM, the global term “diabetic foot” is used [7].  
 
2.1 DIABETIC FOOT LESIONS 
The lifetime risk for a person with DM to develop a diabetic foot lesion could be as high 
as 25% [8]. The development of foot lesions, particularly ulcers, is associated with a 
major burden to the patient. Furthermore, the healing of ulcers is related to high costs 
for society and even higher costs if the ulcer ends in amputation [9–11]. Diabetic foot 
ulcers are also associated with an increased risk of death independent of other 
complications [11–13]. A study from the United Kingdom reported that for patients who 
developed diabetic foot ulcers, 5% died within a year of their first visit to the hospital, 
and 42.2 % died within five years [12]. 
Several factors ultimately lead to skin breakdown and development of foot ulcers in 
patients with DM. These include peripheral neuropathy, vascular diseases affecting the 
arterial circulation, repetitive biomechanical stress and external trauma [7,14]. 
Additionally these ulcers are often complicated by infection [15]. Data from the 
Eurodiale study [16] of 14 European hospitals in ten countries showed that infections 
were diagnosed in 58% of the patients presenting new foot ulcers. Deep infection tends 
to be more rapidly progressive in patients with diabetes, with an associated increased 
risk of lower extremity amputation (LEA) and mortality [17,18]. 
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One of the most important causes of diabetic foot lesions is peripheral neuropathy, 
which affects motor, sensory as well as autonomic nerve functions [19]. Motor nerve 
involvement is associated with loss of neural supply to the muscles, which causes 
limited joint mobility and increased plantar pressure, inducing callus formation [14,20]. 
The damage to sensory nerves results in a loss of protective sensation, permitting 
patients with neuropathy to continue walking despite the presence of foot ulcers [20].  
Sudomotor dysfunction is a common feature of autonomic neuropathy that involves loss 
of sweat and oil gland functions. The skin becomes dry and fissured, and susceptible to 
bacterial invasion [18,21]. Autonomic dysfunction also reduces normal vasoconstriction 
of the vessels and results in increased intraluminal blood flow and pressure. The 
combination of high flow and reduced wall motion encourages the formation of plaque 
in the vessels [22]. 
As mentioned earlier, PAD is another essential factor in the development of diabetic 
foot ulcers, due to an inadequate arterial blood flow to the foot [7]. The Eurodiale study 
reported that PAD was present in around half of the patients diagnosed with new foot 
ulcers [16].  
The cornerstones for treating diabetic foot ulcers are revascularization, surgical 
debridement, antibiotic treatment, offloading and adequate wound dressings. 
Revascularization by percutaneous transluminal angioplasty (PTA) or by-pass surgery is 
crucial for patients with PAD in order to accomplish a good perfusion of the tissue and 
limb salvage [23,24]. Surgical debridement is performed to remove necrotic tissue, as 
well as surrounding calluses, and stimulates the release of growth factors that lead to 
more progressive wound healing. Debridement also reduces plantar pressure at callus 
areas and, by acting on the biofilm situation created by the bacteria in the wound, plays 
an important role in infection control [25–27]. Furthermore, an optimal antibiotic 
treatment is also needed for managing superficial and deep infections [28,29]. Pressure 
relief of ulcers via offloading may be necessary to reduce the pressure and tension on 
plantar foot ulcers. This can be achieved using custom-made insoles and individually 
adjusted footwear [30] or other pressure-relief devices such as a non-removable total 
contact cast to manage plantar neuropathic ulcers [31]. In order to create the ideal 
milieu for healing, an optimal wound dressing is essential [32]. Other methods have 
been suggested as being useful as add-on therapies to gold-standard wound care, e.g., 
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hyperbaric oxygen therapy (HBOT). However, more research is necessary to establish 
adequate evidence of the efficacy and cost-effectiveness of these new methods [33].  
The substantial health economic consequences of patients with diabetic foot lesions 
includes intervention to prevent and heal foot ulcers, and, in cases of amputation, costs 
also associated with the care necessary for post-amputation disability. Studies have also 
shown that the duration of wound healing and repeated surgery as well as healing with 
amputation are important cost driving factors due to multiple and extended 
hospitalization in patients with DM and foot infections [34–37].   
 
2.2 DIABETIC OSTEOARTHROPATHY  
Diabetic osteoarthropathy also known as Charcot foot is a condition affecting the bones, 
joints, and soft tissues of the foot and ankle [38]. The condition may occur as a 
complication of neurosyphilis, syringomyelia, leprosy, poliomyelitis, alcohol abuse, 
traumatic injury, heavy metal poisoning, multiple sclerosis, congenital neuropathy and 
rheumatoid arthritis [39]. However, diabetes has, since it was first associated with 
osteoarthropathy, become the most common etiology for this condition [38] and is the 
focus of paper I of this thesis.   
 
Osteoarthropathy of the small bones in the foot and ankle due to DM is a condition that 
was described by Jean-Marie Charcot in patients with tabes dorsalis in 1883 [40]. 
Herbert William Page preceded Charcot by two years when he presented a case at the 
7th International Medical Congress in London in 1881, something that was in fact 
acknowledged by Charcot and Charles Féré in their 1883 article [41]. The condition has 
thus been known for a relatively long period of time. Nevertheless, the arsenal of 
diagnostic tools and treatment options has remained meager. In fact, up until recently, 
the base of knowledge had not expanded a great deal beyond the publication of  
Charcot´s article [42], although the surgical techniques for reconstruction of the foot 
have improved with the surgical developments of the 20th century. 
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2.2.1 Pathophysiology of diabetic osteoarthropathy 
Diabetic osteoarthropathy is, in the acute phase, presented as an inflammatory warm, 
swollen, and erythematous foot and ankle. The skin temperature of the affected foot 
measures 2-6°C higher than the contralateral foot, and pain may or may not be present, 
depending on the magnitude of the nerve damage [7,43,44]. The acute phase can rapidly 
progress to a chronic stage, if not diagnosed early and properly treated, resulting in 
irreversible foot deformities, e.g., plantar subluxation of the hindfoot, or so-called 
rocker-bottom deformity [38,45]. 
 
There are different theories concerning the origin of diabetic osteoarthropathy: namely, 
a neurotraumatic and a neurovascular theory. The neurotraumatic theory highlights that 
the lack of sensation allows for micro-trauma that leads to the progressive destruction of 
bone and joints. The neurovascular theory suggests that a neutrally initiated vascular 
reflex leads to the activation of osteoclasts, and thus bone resorption and fragility of the 
bone [41]. However, neither of these theories can fully explain the development of 
diabetic osteoarthropathy. A more recent theory [42,46] states that in patients with acute 
diabetic osteoarthropathy, the foot is characterized by an unregulated, local 
inflammatory response to a minor trauma. As a result of the local inflammation, 
proinflammatory cytokines are increased and go beyond control, leading to excessive 
amounts of the protein receptor activator of the nuclear factor kappa B ligand 
(RANKL). RANKL binds to the receptor RANK on the osteoclasts and stimulates their 
maturation and activity, resulting in bone loss [46]. A recent report shows an effect of 
RANKL antibody treatment on diabetes osteoarthropathy [47].  
 
Neuropathy is a well-established factor underlying diabetic osteoarthropathy, leading to 
nerve damage affecting sensation to hot and cold stimuli [48] and abnormal pain 
sensations. As described earlier, diabetic osteoarthropathy often begins with an 
unperceived injury and is then worsened by continuing painless weight bearing. Due to 
limited joint mobility, increased plantar pressures and abnormal walking [49], the 
patients feet are frequently traumatized, which leads to multiple bone fractures. 
 
The pathway of foot fractures in general can be different in patients with type-1 and 
type-2 diabetes. In patients with type 1 DM, fractures are frequently related to 
  
6 
 
peripheral osteopenia and reduced bone mineral density [50]. On the contrary, in type 2 
DM an increased bone mineral density has been observed [51], but bone strength may 
actually be lower due to microarchitectural bone defects leading to bone fragility [52]. 
Diabetic fractures are therefore mainly associated with the alternation of weight bearing 
and the load of the foot. 
 
2.2.2 Diagnosis 
Clinical and radiological diagnoses of acute diabetic osteoarthropathy are challenging 
due to its clinical presentation being similar to what is seen in erysipelas and deep 
venous thrombosis [44]. Also, osteomyelitis could be a differential diagnosis and can 
co-exist with osteoarthropathy in the same extremity [53]. Follow-up of patient with 
DM and acute osteoarthropathy based on signs such as skin temperature, pain, swelling, 
and erythema are useful indicators of the outcome of the disease [54,55] but lack 
specificity and sensitivity. 
 
Different types of classifications have been used to describe the clinical and radiological 
changes of diabetic osteoarthropathy The first classification described was the 
Eichenholtz stages, which correlate to the three physiological stages of healing of a 
fracture: inflammation, repair and remodeling [56,57]. An additional stage 0 has been 
added for early diagnosis, where no detectable radiological changes are found and are 
characterized by inflammatory foot edema [58].The Eichenholtz stages are based on a 
plain x-ray that is used as an initial modality with standardized dorsoplantar and lateral 
radiographs that can also be performed with the patient weight-bearing to assess foot 
alignment and subtle instability [59,60]. An additional pronated oblique position of the 
foot is often included in the examination to clearly demonstrate the tarsometatarsal and 
mediotarsal joints [61]. The earliest finding of  diabetic osteoarthropathy in a plain x-
ray is a widening of joint space and  focal demineralization of bone [62]. A plain x-ray 
can be important for monitoring progression of a developed deformity [44]. However, if 
a radiological method is to be used, the method must be able to detect the condition in 
the acute phase before any bone destruction. Other diagnostic imaging modalities, 
including magnetic resonance imaging (MRI) and nuclear medicine methods, have 
helped to recognize early signs of inflammation and underlying bone damage before 
overt bone and joint destruction has occurred [63].  
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MRI can provide valuable diagnostic information by allowing the early identification of 
soft tissue edema, bone marrow edema, microfractures, hidden fracture lines or 
abnormal bone turnover before it can be seen on radiographs [62,64]. Soft tissue 
inflammatory changes and bone marrow edema is characterized by a decreased signal 
intensity on T1-weighted and high signal intensity on T2-weighted images [44]. Since 
the Eichenholtz classification does not cover the whole spectrum of diabetic 
osteoarthropathy, it has been suggested that they should be abandoned rather than 
extended, and that MRI should replace plain radiography for diagnosing and monitoring 
the affected foot [65].  
 
Bone scintigraphy is a common nuclear medicine procedure and can be useful for the 
evaluation of diabetic osteoarthropathy by revealing an increased uptake along the 
affected bone and joints [58]. A Technetium-99m labeled methylene diphosphonate 
(Tc-MDP) is used for imaging, which is commonly performed in three phases. Imaging 
directly after injection  demonstrates the perfusion of the foot [66]. The second phase 
demonstrates leakage of imaging agents to surrounding soft-tissues/ muscles. After this 
follows the delayed phase, where the tracer uptake mirrors the rate of bone 
remodulation. Additionally, a fourth phase can be added after 24 hours by showing a 
static image that can enhance specificity [44,66]. A disadvantage of scintigraphy is the 
poor spatial resolution and the lack of anatomical landmarks. The more modern hybrid 
systems combining a gamma camera with Computed Tomography (SPECT/CT) can 
overcome this last limitation. 
 
2.2.3 Treatment 
The current standard treatment for osteoarthropathy is immobilization with casting 
therapy. The goal if there is a fracture is to redistribute the plantar pressure to limit bone 
and joint destruction in order to maintain a plantigrade foot with minimal deformity and 
also to prevent further foot fractures. If no fracture has yet appeared, the aim of a total 
contact cast (TCC) is to prevent a fracture [67]. With casting therapy the foot will be 
offloaded, thereby reducing mechanical forces, edema, inflammation and arrest the 
development of the osteoarthropathy [68]. When the affected foot is offloaded with a 
(TCC) [69], the patient has to be checked once every week and the TCC has to be 
changed frequently [38]. Other casting therapies that are used are removable modalities 
  
8 
 
such as orthoses and bivalve casts. To reduce mobility a TCC is preferable as 
compliance with the treatment is thereby enforced [31,70].  
Diabetic osteoarthropathy that allows to develop into deformities of the foot are difficult 
to treat with orthotic devices and can therefore be considered for surgical 
reconstruction. The indications for surgical reconstructions are instability [71], recurrent 
ulcers, inability to heal ulcers, and presence of osteomyelitis and pain [72]. 
 
2.3 GUIDELINES ON THE PREVENTION AND MANAGEMENT OF 
THE DIABETIC FOOT 
Several initiatives have been made to improve diabetic care at both international and 
national levels. In 1989, representatives of government health departments and patient 
organizations from European countries met in Saint Vincent, Italy, under the auspices of 
the World Health Organization (WHO) and the International Diabetic Federation (IDF). 
The meeting resulted in the Saint Vincent Declaration [73], which prescribe some 
fundamental goals for reducing individual and social burdens of diabetes. In the 
declaration, a five-year target was set that there should be a 50 % reduction of lower-
limb amputations for patients with DM. Unfortunately, this has not yet been achieved.   
As a follow-up to the Saint Vincent Declaration, an expert panel met in Stockholm in 
1998 to create consensus on the prevention and treatment of foot ulcers in patients with 
DM on a national level [74]. Physicians and nurses, chiropodists, parliamentarians and 
economists discussed how health care should be organized and how preventive work 
and treatment should be performed. In the consensus statement, they underlined the 
need for implementing MDT in the care of patients with DM and foot problems. In 
1996 the International Working Group on the Diabetic Foot (IWGDF) was founded [75] 
to prevent and reduce the unfavorable effects of diabetic foot problems. Based on 
evidence from high quality studies, the IWGDF continuously update the international 
consensus guidance on recommendations for daily clinical practice of prevention and 
management of foot problems [76]. IWGDF further supported the importance of a 
multidisciplinary approach for treating diabetic foot complications. 
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2.4 MULTIDISCIPLINARY FOOT TEAM 
Major international and Swedish guidelines recommend that patients identified with 
new diabetic lesions should be referred to a dedicated multidisciplinary team (MDT) 
[74,77,78].  
An MDT is a group of specialists with varied, complementary experiences and 
knowledge that contribute to achieve specific objectives in a clinical situation [79].  
The aim for an MDT is to manage patients according to a diabetic foot care process 
through rapid and accurate assessment of the condition of the diabetic foot. An 
important issue for the MDT is to diagnose infection early so that antibiotics and 
debridement can be started immediately, if needed. The MDT task is also to perform an 
assessment of ischemia to evaluate the need for early revascularization [80]. Several 
studies emphasize the importance of an MDT approach that includes preventive 
strategy, patient and staff education, and multifactorial treatment of complex foot 
lesions to obtain satisfactory limb salvation [81–83]. 
According to the Stockholm Consensus Statement [74], different composition of an 
MDT were recommended at different levels – primary care, local hospitals and large 
(university) hospitals. The responsibility of the primary care is to prevent the 
development of diabetic foot lesions and, when necessary, collaboration with a foot 
team at a local hospital. Such a team preferably consists of an internal disease specialist, 
surgeon or orthopedic surgeon, and a chiropodist. They represent a medium level of the 
diabetic foot care assessing foot lesions. Furthermore, some diabetic foot centers are 
recommended to be established in larger hospitals with expertise consisting of a 
diabetologist, diabetes specialist nurse, orthopedic surgeon, vascular surgeon, infectious 
disease specialist, podiatrist, orthotist, radiologist and physical therapists [74]. 
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3 AIMS OF THE THESIS  
The overall purpose of the research described in this thesis was to investigate diabetic 
foot care in Sweden. 
Specific aims: 
The purpose of paper I was to create a national inventory of orthopedic caregivers’ 
organizations for the diagnosis and treatment of diabetic osteoarthropathy. 
The aim of the paper II was to investigate whether the recommendations of the 
Stockholm Consensus Statement regarding the establishment of MDT for the 
management of DM patients with foot complications are being implemented at hospitals 
in Sweden. Furthermore, we also intended to briefly analyze if the work could be 
evaluated by potential quality control markers.  
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4 MATERIALS AND METHODS  
The thesis is based on two parts. Data was collected by structured questionnaires for 
both parts. Based on the “Swedish Association of Local Authorities and Regions” 
registry, the questionnaires were distributed via postal mail to all Swedish hospitals with 
emergency departments. 
 
4.1 PARTICIPANTS 
4.1.1 Paper I 
The head of the orthopedic clinics at each emergency hospital were contacted to identify 
the orthopedic surgeon responsible for the care of patients with foot complications. The 
responsible orthopedic surgeons were then contacted by e-mail with a description of the 
project’s purpose and an announcement that they were going to receive a questionnaire. 
Since 14 of the hospitals were so-called ‘‘joint orthopedic clinics”, with shared 
organizational structures, 63 units received the questionnaire. Three respondents stated 
that they had never dealt with patients with diabetic osteoarthropathy, and therefore the 
analysis was based on responses from 57 clinics. 
 
4.1.2 Paper II 
The questionnaire was sent to all 75 Swedish hospitals with emergency departments. 
Healthcare providers responsible for the diabetic foot care at each hospital were 
identified and received the encoded questionnaire. Information concerning the number 
of beds available at each hospital was collected from the hospital’s webpage. The 
hospitals were then arranged in three groups according to the number of beds available: 
small hospitals < 250 beds; medium-sized hospitals 250-500 beds; and large (university) 
hospitals > 500 beds. Forty hospitals were classified as small, nineteen as medium-sized 
and sixteen as large.  
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4.2. QUESTIONNAIRES 
The questionnaires from the two studies were designed in consultation with the co-
authors of each study. Furthermore the questionnaire in paper I was sent to experienced 
orthopaedic surgeons (not included in the study) for comments on the formulation, and 
the questionnaire in paper II was developed in collaboration between Diabetic Foot 
Center Karolinska (DFCK) and the Swedish Diabetic Association. The questionnaires 
were coded, and a summary of the incoming responses was compiled without 
identifying individual units. No application for ethical approval was needed. 
 
4.2.1 Paper I 
The questionnaire was based on eight questions regarding diagnosis and treatment of 
patients with diabetic osteoarthropathy. We asked how many patients with diabetic 
osteoarthropathy were seen annually and if there were existing guidelines. If there were 
current guidelines, the respondents were asked to include them when returning the 
questionnaire. Furthermore, we asked about methodology used to diagnose diabetic 
osteoarthropathy, how soon after suspicion of the disorder the patient obtained an 
appointment time, and what treatment the patient received as well as the duration of 
treatment. The respondents were also questioned whether they had access to 
reconstructive foot surgery for foot deformities caused by diabetes osteoarthropathy. 
 
4.2.2 Paper II 
The questionnaire consisted of eight questions regarding which hospitals had an MDT 
and their access to different specialists, as well as these specialists’ attendance in the 
MDT evaluation in outpatient care and for hospitalized patients. Additionally, we asked 
if they had treatment guidelines, and if the hospitalized patients were in a specialized 
ward or if their beds were in various wards.   
 
The questionnaire also contained questions regarding quality control markers, such as a 
local registration of the annual number of amputations on patients with DM as well as a 
registration of healed ulcers. We also asked if patients received written information for 
their general practitioner and district nurse when visiting the clinic.  
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4.3 DATA ANALYSIS  
The data were downloaded into Microsoft Excel, and analyzed and computed in terms 
of frequencies and percentages using the Statistical Package for Social Sciences (SPSS) 
Windows version 22.0. The received guidelines in study I were assessed using diabetic 
(Charcot) foot management directives from the American Academy of Orthopaedic 
Surgeons (AAOS) [84]. 
 
4.4 ETHICAL CONSIDERATIONS 
No application for ethical approval was done. According to ethical principles [85], all 
respondents were informed about the overall purpose and features of the project in 
which they were agreeing to participate. All participation was voluntary. The 
respondents were also informed that the questionnaires were coded and the responses 
that were received were compiled without presentation of their individual units. 
Additionally, data collected for the purposes of this research will not be used for 
commercial or other non-scientific purposes. 
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5 RESULTS 
5.1 PAPER I 
The questionnaires were sent to 63 Swedish hospitals with emergency departments for 
orthopedic patients. We received responses from 60 hospitals and experienced a 95 % 
response rate. Three respondents returned the questionnaire with the reply that they did 
not manage patients with diabetic osteoarthropathy. They did not answer the questions 
in the questionnaire and are, therefore, not included in the analysis. We asked the 
remaining 57 hospitals how many patients they estimated handling at the clinic annually 
(Table 1). Most of the respondent reported managing one to five patients every year. 
 
Table 1. Estimated number of patients with diabetic osteoarthropathy managed annually.  
Number of patients n=57 (%) 
0 4 (7 %) 
1-5 26 (45,6%) 
6-10 8 (14 %) 
>10 15 (26,3 %) 
Do not know 2 (3,5 %) 
No answer 2 (3,5 %) 
 
Out of the 57 hospitals included in the analysis, 10 claimed to have established 
guidelines for managing patients with diabetic osteoarthropathy. However, when asked 
to bring the guidelines together with the questionnaire, only seven were included. 
Furthermore, when evaluating the guidelines according to the recommendations by the 
AAOS [84] only two were assessed as adequate. 
Only 2 of the respondents responded that patients with suspected diabetic 
osteoarthropathy made an appointment at their clinic within 1 day, 26 stated that it took 
1-5 days and 18 clinics answered > 5 days. Additionally, 11 respondents did not know. 
Most of the respondents used several methods to diagnose patient with diabetic 
osteoarthropathy. Fifty-four clinics stated that they performed a clinical diagnosis 
followed by plain X-ray (table 2). In addition, 37 clinics complemented the diagnosis 
with an MRI and/or bone scintigraphy. 
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Table 2. Methodology used to diagnose diabetic osteoarthropathy 
Method for diagnosis n=57 (%) 
Clinical diagnosis 54 (95,5 %) 
Skin temperature 31 (54 %) 
Plain X-ray 54 (95,5 %) 
Bone scintigraphy 6 (11,5 %) 
MRI 34 (60 %) 
Do not know 1 (1%) 
 
The responses concerning the treatment methods indicated that 47 clinics used a TCC, 
and 31 clinics stated that a TCC was the only casting treatment they used, 5 used 
orthoses alone and 1 used only a bivalve cast, which is a removable cast. In combination 
with a TCC, 26 clinics used different casting treatments, while 3 respondents stated that 
they did not know. In a few cases, additional options were also specified such as the 
Don Joy Walker (2%), the Walker from Össur (2%) and PTB Orthosis (2%). Ten of the 
responding clinics specified having an orthosis option, despite having only listed the 
total contact cast as a treatment method. 
 
Table 3. Treatment duration for patients with diabetic osteoarthropathy 
Treatment duration n=57 (%) 
No treatment 2 (3,5 %) 
<3 months 2 (3,5 %) 
3-6 months 30 (52,6 %) 
6-12 months 16 (28,1 %) 
>12 months 4 (7 %) 
No answer 3 (5,3 %) 
 
Of the 57 clinics, 34 claimed having access to reconstructive foot surgery for diabetic 
osteoarthropathy, 11 referred the patient to the nearest university hospital and 9 to the 
regional hospital. Two clinics reported not knowing, and one referred the patients to 
other unspecified clinics. 
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5.2 PAPER II 
Out of all 75 Swedish hospitals with emergency departments that received the 
questionnaire, 69 responded, resulting in a 92 % response rate. As the hospitals have 
different conditions for MDT work, the responses that were received were grouped and 
presented according to size: small hospitals, medium-sized hospitals and large hospitals. 
Out of the questionnaires that were received, 11 claimed to have no access to an MDT 
(Fig 1). Only the hospitals claiming to have access to an MDT were included in further 
analysis. 
 
Figure 1. The number of hospitals with access to an MDT, according to size. 
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Table 4. Specialists the MDT reported having access to. 
Specialists  Small 
hospitals 
n=26 (%) 
Medium-sized 
hospitals 
n=16 (%) 
Large 
hospitals 
n=16 (%) 
Total 
n=58 (%) 
Specialist in general 
internal medicine 
8 (31 %) 0 (0 %) 1 (6 %) 9 (16 %) 
Diabetologist 15 (58 %) 15 (94 %) 15 (94 %) 45 (78 %) 
Specialist in orthopaedic 
surgery 
9 (35 %) 3 (19 %) 3 (19 %) 15 (26 %) 
Orthopaedic surgeon 
with experience in foot 
surgery 
8 (31 %) 12 (75 %) 10 (63 %) 30 (52 %) 
General infectious 
disease specialist  
9 (35 %) 5 (31 %) 9 (56 %) 23 (40 %) 
Infectious disease 
specialist with 
experience in orthopedic 
infections 
2 (8 %) 10 (63 %) 3 (19 %) 15 (26 %) 
General vascular surgeon 6 (23 %) 2 (13 %) 1 (6 %) 9 (16 %) 
Vascular surgeon with 
experience in extremity 
surgery 
5 (19 %) 8 (50 %) 9 (56 %) 22 (38 %) 
Podiatrist 25 (96 %) 16 (100 %) 15 (94 %) 56 (97 %) 
Orthotist 23 (89 %) 15 (94 %) 15 (94 %) 53 (91 %) 
Diabetes specialist nurse 23 (89 %) 13 (81 %) 8 (50 %) 44 (76 %) 
 
Participation of all specialists decreased in the MDT evaluation of hospitalized patients 
(Table 6) in comparison to outpatients (Table 5). The main difference was in the 
participation of the chiropodist and the orthotist, where the attendance decreased by 32 
% for the podiatrist and 34% for the orthotist. 
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Table 5. Specialists attending the MDT evaluation of outpatients 
Specialists  Small 
hospitals 
n =26 (%) 
Medium-sized 
hospitals 
n=16 (%) 
Large 
hospitals 
n=16 (%) 
Total 
n=58 (%) 
Internal medicine 
specialist 
23 (88 %) 15 (94 %) 14 (88 %) 52 (90 %) 
Orthopaedic surgeon 12 (46 %) 13 (81 %) 11 (69 %) 36 (62 %) 
Infectious disease 
specialist  
6 (23 %) 14 (88 %) 10 (63 %) 30 (52 %) 
Vascular surgeon 5 (19 %) 7 (44 %) 1 (6 %) 13 (22 %) 
Podiatrist  24 (92 %) 16 (100 %) 15 (94 %) 55 (95 %) 
Orthotist 22 (85 %) 14 (88 %) 15 (94 %) 51 (88 %) 
 
Table 6. Specialists attending the MDT evaluation of hospitalized patients. 
Specialists  Small 
hospitals 
n=26 (%) 
Medium-sized 
hospitals 
n=16 (%) 
Large 
hospitals 
n=16 (%) 
Total 
n=58 (%) 
Internal medicine 
specialist 
19 (73 %) 8 (50 %) 8 (50 %) 35 (60 %) 
Orthopaedic surgeon 10 (39 %) 7 (44 %) 11 (69 %) 28 (48 %) 
Infectious disease 
specialist  
6 (23 %) 11 (69 %) 7 (44 %) 24 (41 %) 
Vascular surgeon 3 (12 %) 4 (25 %) 5 (31 %) 12 (21 %) 
Podiatrist  14 (54 %) 5 (31 %) 4 (25 %) 23 (40 %) 
Orthotist 9 (35 %) 4 (25 %) 4 (25 %) 17 (29 %) 
 
Sixty percent of the hospitals have a specialized ward (50 %, 69 %, and 69 % 
respectively according to size) for hospitalization of the patients, and ten percent report 
having both scattered beds and a specialized ward (4 %, 19 %, and 13 % respectively). 
Fifty percent of the hospitals with MDT reported having scattered beds (54 %, 50 %, 
and 44 % respectively).  
When the hospitals were asked whether they had established guidelines for managing 
patients with DM and foot ulcers, 67% claimed they had. Furthermore, 57% stated that 
the patients received written information (“treatment message”) for their general 
practitioner and primary care nurse when visiting the clinic. 
The hospitals were also asked whether there was a local registration of the annual 
number of amputations and healed foot ulcers as potential quality control markers for 
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evaluating their work. Of all hospitals included in the analysis, 48 % reported having 
local registration of the annual number of amputations and 21% for healed foot ulcers 
(Fig. 2). 
 
Figure 2. Number of hospitals with local registration of the annual number of amputations and 
healed ulcers. 
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6 DISCUSSION  
Long-term diabetes-related complications are likely to become more common, due to 
the increasing prevalence of the disease [1]. In particular, the diabetic foot is associated 
with reduced health-related quality of life and substantial costs for the society. This is 
further accentuated if the outcome is amputation, resulting in prolonged hospitalization 
and need for rehabilitation and home care [86–91]. 
In accordance with recently reported audits in other countries, especially the United 
Kingdom, there can be a certain value in national surveys for evaluating the care of 
patients with DM, allowing an organization to deal with inadequacies in its management 
[92–97].  
 
6.1 DIABETIC OSTEOARTHROPATHY CARE  
In Sweden today, there is no official record concerning the incidence of 
osteoarthropathy in patients with DM. Neither do we know the consequences of a 
diabetic osteoarthropathy diagnosis. The incidence of diabetic osteoarthropathy is likely 
to be underestimated due to failure to recognize the initial clinical manifestation of a hot 
swollen foot [98,99]. Furthermore, there have been reports of misdiagnosis and delay of 
treatment [43,100] explained by the patient´s lack of protective sensation. In paper I, we 
have only arrived at an estimated number of patients with diabetic osteoarthropathy 
from the respondents. There seem to be a need to investigate this further at the national 
level. It is likely that some kind of a national registration linked to the Swedish national 
diabetes register will be necessary to arrive at the real incidence. Previous studies have 
tried reporting the incidence of diabetic osteoarthropathy. A retrospective study from 
Denmark [101] followed an average of 4,000 patient over a 10-year period. An annual 
incidence of diabetic osteoarthropathy of 0.3 % in a population with diabetes was found. 
Each patient presented a red warm swollen foot with radiological evidence of 
osteoarthropathy. Another study reported an incidence of 8.5/1,000 per year in Hispanic 
whites and Mexican Americans diagnosed with diabetes [8]. In this study, 
osteoarthropathy was defined as a lower extremity fracture or dislocation in the 
presence of sensory neuropathy with loss of protective sensation. This indicates that 
diabetic osteoarthropathy should be considered in all patients presenting with 
neuropathy, edema, erythema, and increased temperature of the foot. If the diabetic 
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osteoarthropathy of the foot can be recognized without delay, followed by immediate 
offloading, fractures and incapacitating deformities can be minimized, and devastating 
morbidity and mortality substantially decreased [102]. In addition, a delayed diagnosis 
of diabetic osteoarthropathy results in a significantly increased acute health care cost 
and longer hospitalization time. A recent study showed that a delayed osteoarthropathy 
diagnosis was associated with a 10.8 % greater inpatient cost and 12.1 % longer 
hospitalization time [103].  
When asking about the methodology that was used to diagnose diabetic 
osteoarthropathy, 65 % reported further investigation of patients with MRI and/or bone 
scintigraphy after the clinical examination and the plain X-ray. Studies have shown that 
MRI and bone scintigraphy can reveal pathological changes that correlate with diabetic 
osteoarthropathy in patients after the onset of erythema, edema, swelling and increased 
temperature of the foot when a plain x- ray is considered normal [102]. MRI showed 
bone marrow edema, and bone scintigraphy with Technetium 99m showed increased 
isotope uptake, which is, however, nonspecific and cannot differentiate between 
osteomyelitis and osteoarthropathy. The value of bone scintigraphy is therefore limited 
to negative results and excluding of bone engagement. Another useful nuclear medicine 
method in diagnosing inflammatory and infectious entities is positron emission 
tomography (PET) using the tracer fluorodeoxyglucose (FDG). FDG is a variant of 
glucose with the same uptake in cells as regular sugar. Since inflammatory cells need 
more glucose than healthy cells, there is an increased uptake of FDG in inflammatory 
areas seen on the FDG-PET image [104]. Despite the high sensitivity, there is limited 
specificity [105].  
Computed tomography may be useful in detecting cortical bone destruction and 
periosteal bone formation, but it cannot differentiate between purulent, granulation 
tissue, inflammation, or fibrosis [106]. However, CT in combination with positron 
emission tomography (PET), so-called PET-CT, or single- photon emission (SPECT) 
CT can correlate anatomical location with areas of uptake contributing to bone marrow 
evaluation [44,63]. Moreover, studies have indicated that fluorodeoxyglucose (FDG) 
PET can reliably distinguish diabetic osteoarthropathy from osteomyelitis both in 
general and with the presence of a foot ulcer [107–109]. These publications are based 
on a small number of observations, and larger clinical trials are needed to establish the 
role of FDG-PET/CT in these patients. Furthermore, the low availability of PET/CT 
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may be a limiting factor in using these hybrid imaging methods. Other diagnostic 
imaging methods like sonography may visualize abnormalities on the surface of the 
bone [106]. 
In paper I, 47 clinics claimed to use TCC even if they also reported using alternative 
casting treatments, e.g., a bivalve cast or/and orthoses. Whether these casting modalities 
followed each other during the same treatment period is unclear. In the active stage, the 
foot affected with osteoarthropathy should be immobilized and offloaded until the 
inflammation subsides and the fractures heals [67,110], and TCC has been suggested as 
the current standard therapy [67,111,112]. However, there are controversies associated 
with the non-removable or removable cast [110]. Previous studies have shown that TCC 
was the first choice of management in fewer than half the cases [113,114]. Furthermore, 
strict non-weight-bearing therapy of the affected foot can lead to unfavorable 
consequences on the contralateral, non-affected foot due to increased mechanical forces. 
People with TCC-treated diabetic osteoarthropathy also have a risk of falling because of 
increased instability. Furthermore, immobility has a disadvantage due to loss of muscle 
tone and bone density [38]. The duration of casting therapy has also been debated. In 
the study question concerning the treatment duration for patients with osteoarthropathy, 
we provided the respondents with the options <3 months and 3-6 months, etc. Previous 
clinical studies indicate no further reduction of bone mineral density of the Charcot foot 
after three months of casting therapy, although the foot was treated until clinical 
resolution [42,115]. Additionally, the increased concentration of proinflamatory 
cytokines TNF-α and interleukin-6 in osteoarthropathy are significantly reduced after 
three months of casting therapy with no further changes measured at clinical resolution 
[42]. The clinical resolution was defined as the time lapsing before the temperature 
difference between the feet was < 2°C at two consecutive monthly visits. 
Diabetic osteoarthropathy that develops with deformities are challenging to treat 
surgically as these operations are associated with a high rate of complications [116]. 
There is, therefore, emphasis on the need for orthopaedic foot surgeons with vast 
experience in various surgical approaches, because the quality of the soft tissue is 
decisive as to which approach can be employed [72]. 
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6.2 MDT CARE 
In the inventory of MDT management of patients with DM and foot complications, 
most of the respondents claimed having some kind of organized MDT for diabetic foot 
care. However, due to the complexity and multifactorial manifestation of the diabetic 
foot, the composition of the team can be of utmost importance to the outcome. In the 
case of successful organized MDT care, there can be a reduction of LEA, length of 
hospitalization and death rates [117,118]. A study from the university hospital in Lund, 
Sweden reported that two-thirds of patient with diabetic foot ulcers healed without 
amputation when treated in an MDT, even if the time to heal the ulcers was long [119]. 
The MDT consisted of a diabetologist, an orthopaedic surgeon, a nurse specializing in 
diabetes, an orthotist and a chiropodist, and the team also cooperated and had access to 
vascular surgeons and specialists in infectious diseases. Moreover, an MDT approach 
has shown to be successful in other areas such as the rehabilitation of patients with 
chronic pain, as it leads to better coping, lower depression scores and higher social 
activity, which contributes to lower sick leave [120,121]. Furthermore, MDT in cancer 
care has also reported multiple benefits such as more accurate treatment 
recommendations and adherence to clinical guidelines, improved quality of life for 
patients [122–124] and significantly shorter intervals between diagnosis and treatment 
[125]. However, the need for clarified roles for the different health professions included 
in the MDT has been highlighted due to the overlapping areas of expertise [122,126]. 
 
6.3 MEMBERS OF THE MDT 
In about half of the teams, infectious disease specialists (52 %) attended the MDT joint 
evaluation of outpatients, but the attendance decreased to 41% in the evaluation of 
hospitalized patients. There was also low access to vascular surgeons, and they only 
attended the joint evaluation in just over 20% in both inpatient and hospitalized patients, 
regardless of playing an important role in the management of the diabetic foot by 
performing assessments of ischemia and evaluating needs for and types of 
revascularization [80]. Since ischemic complications are common in patients with 
diabetic foot disease, it is important to diagnose infection in order to immediately start 
adequate antibiotic treatment and evaluate the need for debridement. Additionally, 
according to the results of the Eurodiale study [16], more than half of diabetic ulcers 
become infected, which also indicates the need for the attendance of an infectious 
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disease specialist (preferable with competence in orthopaedic infections) in MDT care 
of the diabetic foot. 
We did in our study notice a reduction in the attendance of all specialists in the joint 
MDT assessment of hospitalized patients compared to outpatients. These patients in 
their clinical situation should instead have maximal access to an optimal MDT. 
Essential skills for the care of hospitalized patients include the ability to stage a foot 
wound, to assess peripheral vascular disease, to treat neuropathy and wound infections, 
and the need for debridement [127]. Here we observe an area for improvement. 
In many countries, the podiatrist plays a key role in MDT diabetic foot care [82,128–
131] by managing foot ulcers through appropriate wound care, prevention of recurrence 
and also by applying proper offloading strategies [129,132]. Currently, there is no 
higher education program for becoming a podiatrist in Sweden. 
 
6.4 TELEMEDICINE 
Results from the two studies indicate a need for collaboration between hospitals with 
different resources and access to specialists. In paper I, 14 hospitals had joint 
orthopedics clinics, and 23 hospitals needed to referee the patients to another hospital 
for reconstructive surgery for foot deformities. In addition, paper II showed that some of 
the small and medium-sized hospitals in Sweden did not have access to a foot team, but 
referred the patients to hospitals with MDT competence. In order to be able to provide 
equal care for everyone, telemedicine could offer a solution by connecting small 
hospitals with specialists in larger hospitals in order to deliver health care and to share 
medical knowledge over distances. Patients with diabetic foot complications need 
frequent access to specialized care, and telemedicine could therefore also be a solution 
for primary care by reducing the need to visit the hospital and to promote equal care 
regardless of where the patient lives. The benefits of telemedicine not only consist of 
increased access to health services, but has also shown to be cost-effective, with 
improved health outcomes and quality of care leading to a better quality of life as well 
as enhanced educational opportunities for both health care providers and patients 
[133,134]. A report has shown that patients with chronic diseases such as diabetes want 
to be more active in their own care and to gain knowledge about the diagnosis and how 
to manage daily life [135]. 
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Radiology services is one of the medical specialties that have embraced telemedicine 
technology in order to deliver optimal services in rural areas that are sparsely populated 
[136,137]. The need for delivering healthcare and sharing medical knowledge over a 
distance using telecommunication systems is not new: the first attempts were made in 
the early 1960s [138]. There was little advancement in the following decades, but in 
1990 the development of capturing images and other data in digital electronic form 
made it possible for teleradiology to advance. Teleradiology could than start to solve 
medical needs to improve quality in a cost-effective way.  
Telemedicine has been implemented to a limited extend in diabetes foot care delivery. 
A recent study of health care professionals´ experiences with telemedicine in diabetic 
foot care [139] indicated that increased contact between primary health care and 
specialist health care made communication between the two more efficient and saved 
time. A literature review from 2007 on the contribution of telemedicine confirms these 
findings [140]. Additionally, the review indicated that teleconsultation and 
videoconferencing could be cost-effective and reliable ways of providing diabetic care.  
 
6.5 QUALITY MEASURES 
The incidence of amputation has been suggested as a marker of quality of diabetic foot 
care [73]. Furthermore, in patients with diabetic foot disease, LEA, along with 
blindness, is most commonly reported as the most feared complication of DM [141]. 
However, the incidence of amputation is dependent on several factors that need to be 
taken into consideration when using amputation as a quality marker. The incidence is 
not only dependent on the severity of the disease, the quality of specialist care, 
professional opinion and the organization of local health services, but also on cultural 
and social issues [142]. Healed ulcers have also been used as quality markers of diabetic 
foot care; however, these measures alone do not provide any information on the health 
economy. Furthermore, they do not take into account vital aspects, such as functional 
ability and quality of life of the patients [126,143]. 
Studies from Norway and Denmark on the evaluation of diabetic foot ulcer teams also 
emphasize the need for quality improvement and adherents to guidelines [144,145]. In 
Norway, 17 out of 41 hospitals had diabetic foot ulcer teams, and only 9 foot teams had 
written routines for assessment [144]. Out of the 23 respondents in the Danish 
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evaluation, 42 % reported having an MDT in accordance with the national guidelines 
[145]. These results indicate the need for recurrent evaluation of MDT care of patients 
with DM and foot complications so as to find areas for improvement. 
 
6.6 COMMENTS 
A strength of the two studies was the positive attitude among the responding clinics to 
participate in the evaluations, which led to a high response rate. This might reflect how 
important they believe their work to be. The limitation of the studies is that we can only 
make an assumption based on the answers reported by the respondents. As in most 
questionnaire surveys, questions can often be interpreted in different ways.  
Data were collected using structured questionnaires with response options provided, 
primarily, which obviously limits the opportunities for respondents to express 
themselves. In paper I, only conventional plain radiography, bone scintigraphy and 
MRI were given as response options concerning diagnostic imaging. However, other 
diagnostic methods are currently under evaluation but are not considered as clinical 
routines in Swedish hospitals. 
 
A weakness of paper I is that the primary care physicians who might be the first health 
care contact of patients were not part of the inventory. Our findings indicate the need 
for further assessment of the caregiving of these patients also at the primary care level. 
However, we believe that as diabetes osteoarthropathy is an orthopedic issue, especially 
with respect to reconstructive surgery, it demands the highest and optimal mindset at the 
orthopedic clinic, in order to minimize the consequences of this rather rare but 
devastating complication. The knowledge of the orthopedic clinics should then actively 
and regularly be transferred to the primary care level. A limitation of paper II is that a 
pilot version of the questionnaire, developed in collaboration between DFCK and the 
Swedish Diabetic Association, was not created and evaluated before the final version 
was distributed.  
As in most questionnaire surveys, questions can often be interpreted in different ways. 
Our study is no exception. In one of the questions, we ask which specialists the foot 
team has access to. These specialists do not have to be part of the team per se but can be 
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accessed via, e.g., referral or a phone call. Some respondents may have interpreted the 
question narrowly as an inquiry into which specialists were part of the foot team.  
Furthermore, we asked which specialists attended the MDT evaluations of outpatient 
and hospitalized patients. The idea behind an MDT approach is that all specialists 
examine a foot at the same time in the same room, with each contributing different 
knowledge on the clinical situation, resulting in an improved care of the patient. In 
some cases, there seemed to be confusion about the actual meaning of the 
multidisciplinary approach concept. 
When asking whether the hospitals had a local register of the annual number of 
amputations and healed ulcers, perhaps it should have been emphasized that the NDR 
(National Diabetes Register) is a central register and not a local register.  
 
6.7 CONCLUSION  
The inventory of diabetic osteoarthropathy care in Sweden clearly indicates a need for 
an improvement in knowledge at the national level as well as guidance and organization 
regarding the care of patients with osteoarthropathy. An international consensus 
discussion is also recommended in order to reach and maintain the optimal level of 
diagnosis and management of patients with suspected diabetes osteoarthropathy. 
The MDT approach to patients with DM and foot complications has become established 
in Sweden, but there is a need for further improvement, especially for hospitalized 
patients and in small, local hospitals. Furthermore, the role of MDT needs to be clarified 
and extended in order to improve the quality of care. 
Our study indicates that anational surveys can be a valuable tool in evaluating health 
care organizations and management in order to reach and maintain adequate and 
equivalent care for patients. This evaluation can also be used in identifying fields for 
further clinical research and bring opportunity for knowledge transfer. 
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